CRISPR Therapeutics (CRSP) Tops Q3 EPS by 9c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $890 thousand versus the consensus estimate of $9.41 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• TD Cowen: '2Q26 Digital Ad Expert Call: Resilient Consumer Continues to Drive Ad Spend'
• Microbot Medical reports over 100% revenue growth in Q2 2026
• BlackSky wins U.S. R&D contracts for AI-based satellite ISR tools